



# MARKET RELEASE

11 August 2015

**Asian American Medical Group Limited**

**TRADING HALT**

The securities of Asian American Medical Group Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 14 August 2015 or when the announcement is released to the market.

Security Code:           AJJ

Adrian Smythe  
**Manager, Listings Compliance**

For personal use only



11 August 2015

Mr Adrian Smythe  
Australian Securities Exchange  
Electronic Lodgment

Dear Adrian,

### **REQUEST FOR TRADING HALT**

The Board of the Asian American Medical Group Limited ("AAMG") formally request a trading halt for its securities effective the close of trading on the 11 August 2015.

The reason for the trading halt is that AAMG is in final stages of concluding an agreement for a significant acquisition. AAMG expects to make an announcement about the conclusion of the agreement within the next two trading days.

AAMG requests a trading halt for the next two trading days.

The company is not aware of any reason why the trading halt should not be granted.

On behalf of the Board



**DARIO NAZZARI**  
Company Secretary

### **About Asian American Medical Group**

**Asian American Medical Group ("AAMG")** is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group's operations include the Asian American Liver Centre Pte Ltd ("AALC"), established in 1994 in Singapore, and Asian American Radiation Oncology Pte Ltd ("AARO").

The Group entered into a strategic collaboration in October 2012 with the US-based US\$11-billion integrated global health enterprise UPMC. UPMC, ranked No. 12 on the U.S. News & World Report Honor Roll of American's Best Hospitals, is affiliated with the University of Pittsburgh Schools of the Health Sciences and are pioneers in the field of transplantation. This collaboration has enhanced AAMG's clinical capabilities through shared protocols,

rigorous quality standards and technology and also created a platform for AAMG to expand into other countries in Asia such as Malaysia and Myanmar.

AALC, one of Asia's foremost liver centres, is led by renowned hepatobiliary and liver transplant surgeon, Dr. Tan Kai Chah (Dr. KC Tan), who helped start the Liver Transplant Programme at the King's College Hospital London, UK, and pioneered the highly successful Living Donor Liver Transplantation (LDLT) Programme in Singapore.

AARO, established in March 2015, offers radiation oncology consultancy and management and is spearheaded by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.

For further information, please visit [www.aamg.co](http://www.aamg.co).

**Media enquiries**

WeR1 Consultants

Ms Sheryl Sim; [sheryl@wer1.net](mailto:sheryl@wer1.net)

Ms Rachael De Foe; [rachaeldefoe@wer1.net](mailto:rachaeldefoe@wer1.net)

Tel: +65 6737 4844

For personal use only